

1 **Circulation of DENV-2 serotype associated with increased risk of cumulative incidence of severe**  
2 **dengue and dengue with warning signs: A 16-year retrospective study in Peru.**

3

4 **Jorge L. Cañari-Casaño<sup>1\*</sup>, Valerie A. Paz-Soldan<sup>1,2</sup>, Andres G. Lescano<sup>3</sup>, Amy C. Morrison<sup>4</sup>**

5 <sup>1</sup> One Health Research Unit, School of Public Health and Administration, Universidad Peruana  
6 Cayetano Heredia, Lima, Peru

7

8 <sup>2</sup> Tropical Medicine and Infectious Disease, Tulane School of Public Health and Tropical Medicine,  
9 New Orleans, Louisiana, US

10

11 <sup>3</sup> Emerge, Emerging Diseases and Climate Change Research Unit, School of Public Health and  
12 Administration, Universidad Peruana Cayetano Heredia, Lima, Peru

13

14 <sup>4</sup> Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine,  
15 University of California, Davis, California, US

16

17 \* Corresponding author

18 E-mail: [jorge.canari@outlook.com](mailto:jorge.canari@outlook.com)

19

20

21

22

23

24

25

26

27

28

29

30

## 31 **Abstract**

32 **Background:** Dengue poses a significant public health challenge in Peru and other endemic countries  
33 worldwide. While severe dengue is known to be associated with secondary infection at the individual  
34 level, the factors that elevate the risk of severe dengue at the population level remain poorly understood.  
35 This study leverages over 16 years of secondary data from a Peruvian dengue surveillance system to  
36 assess which type of serotype-specific circulation is associated with an increased risk of cumulative  
37 incidence of severe dengue or dengue with warning signs (SD-DWS).

38 **Methodology:** This is a retrospective analysis of secondary data using the Peruvian Ministry of Health  
39 databases of dengue cases and serotyping. A mixed negative binomial regression model for repeated  
40 measures over time was employed to estimate the association between the cumulative incidence of  
41 reported SD-DWS cases per 100,000 inhabitants and serotype-specific circulation. Crude and adjusted  
42 incidence ratios (IRR) were estimated.

43 **Principal findings:** The study analyzed data from 2007 to 2022 across 19 regions of Peru, totaling 304  
44 region-years. Data from nearly 58,000 serotype identification reports and 57,966 cases of SD-DWS  
45 were analyzed. The regions with most cumulative incidence of SD-DWS per 100,000 inhabitants during  
46 2007 to 2022 were Madre de Dios (3859), Loreto (1518), Ucayali (1492), Tumbes (1335), and Piura  
47 (722). The adjusted model revealed a higher risk of cumulative incidence of SD-DWS when there was  
48 specific circulation of DENV-123 (aIRR 7.57 CI 4.00 – 14.31), DENV-12 (aIRR 4.66 CI 2.57 – 8.44),  
49 DENV-23 (aIRR 3.55 CI 1.75 – 7.21), or when there was circulation of DENV-2 alone or co-circulating  
50 with other serotypes (aIRR 27.7 CI 15.46 -49.63).

51 **Conclusions:** Circulation of DENV-2 was associated with higher average incidence rate ratios of SD-  
52 DWS.

53 **Keywords:** Dengue, Serotypes, dengue severity.

54

55

56

57

## 58 **Author summary**

59           We investigated how the circulation of different dengue virus (DENV) serotypes are associated  
60 with the incidence of severe dengue and dengue with warning signs in Peru, a country where dengue is  
61 endemic. We analyzed 16 years of data from the dengue surveillance system, including nearly 58,000  
62 serotype identification reports and 57,966 cases of severe dengue and dengue with warning signs. We  
63 found that regions with specific circulation of DENV-2, either alone or in combination with other  
64 serotypes, had higher incidence rates of severe dengue and dengue with warning signs. Our findings  
65 highlight the importance of monitoring DENV serotype circulation to manage and prevent severe  
66 dengue, especially in regions where DENV-2 is prevalent.

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

## 83 Introduction

84 Dengue, a significant public health issue, is endemic in Peru, as in other tropical climates. It is  
85 caused by an RNA virus with four known serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) [1].  
86 The dengue virus (DENV) is primarily transmitted through the bite of an infected female mosquito of  
87 the *Aedes* genus: in Peru, it is mainly transmitted by *Aedes aegypti* [2,3].

88 Most of the dengue research in Peru has been carried out in the Amazonian city of Iquitos.  
89 These studies have shown that since the reintroduction of dengue in Peru in 1990, all four DENV  
90 serotypes (including the introduction of new genotypes) have circulated [4–6]. In addition, Peru has  
91 experienced several epidemic outbreaks (2001/2002, 2011/2012, 2017, and 2023) with a high number  
92 of cases of severe dengue (SD) or dengue with warning signs (DWS) (SD-DWS), sometimes  
93 overwhelming or collapsing health systems [2,7].

94 For an individual, a secondary DENV infection with a heterologous serotype is one of the  
95 primary risk factors for severe dengue [8–12]. At the population level, the risk of severe disease may  
96 be associated with 1) an increase in the population susceptible to second infections, 2) the sequential or  
97 co-circulation of multiple DENV serotypes [13], and 3) a rise in the overall force of infection, increasing  
98 the number of all cases across the clinical spectrum of disease and the probability that individuals  
99 susceptible to a second infection become infected. Additionally, inadequate disease surveillance and  
100 vector control, inadequate or improper case management, all contribute to the public health  
101 consequences of dengue outbreaks, and particularly, of severe disease.

102 Due to the low prevalence of severe dengue (less than 1% of total dengue cases [3]),  
103 identification of specific risk factors for SD-DWS requires multiple years (decades) of surveillance to  
104 achieve adequate statistical power for analyses. Our study leverages 16 years of Peruvian dengue  
105 surveillance system data to evaluate potential serotype-related risk factors (what and how many  
106 serotypes are circulating) associated with increased incidence of SD-DWS.

107

## 108 **Methods**

### 109 **Ethics statement**

110 Our secondary data protocol was approved by the institutional review board of the Peruvian  
111 University Cayetano Heredia (SIDISI 207993, approval record number 079-01-22). The anonymized  
112 data was obtained through the public information system of the Peruvian Ministry of Health.

113

### 114 **Data sources**

115 Data was acquired from the National Center for Epidemiology of Peru (CDC-Peru), a branch  
116 of the Ministry of Health. We extracted all reported dengue cases and serotyping data collected between  
117 2007 and 2022. Reporting of dengue cases is mandatory for both public and private health centers  
118 nationwide [14]. This surveillance system reports both confirmed and probable cases. Confirmed cases  
119 are those with laboratory confirmation by DENV isolation, RT-PCR, NS1 antigen, detection of IgM  
120 antibodies for dengue in a single sample, and/or evidence of IgM seroconversion in paired samples.  
121 Probable cases correspond to those that occur during outbreaks, meet case definitions set by the World  
122 Health Organization [15] or by epidemiological link for patients who had direct contact with confirmed  
123 cases [14]. Overall, 90% of cases in our database were classified as confirmed and 10% represented  
124 probable cases.

125 A small proportion of these confirmed cases are analyzed in regional reference laboratories to  
126 identify the circulating serotype using multiplex RT-PCR [16]. Subsequently, the serotype  
127 identification reports are registered in the database system of the Peruvian Public Health Laboratory  
128 Network (NETLAB) [17] of the Ministry of Health. Dengue case data and serotype identification data  
129 were requested from the Ministry of Health through their public access website [18].

130

### 131 **Study variables**

132 Our principal outcome variable was the cumulative incidence of SD-DWS per 100,000  
133 inhabitants, associated with explanatory serotype-specific circulation variables. We calculated the

134 cumulative incidence of SD-DWS per 100,000 inhabitants for each region and year by dividing the total  
135 number of SD-DWS by the projected population, estimated by year by the National Institute of Statistics  
136 and Informatics (INEI) using census data. We also estimated a global summary of the cumulative  
137 incidence of SD-DWS per 100,000 inhabitants for each region over the 16-year study period, by  
138 dividing – per region (Peruvian state) – the total number of SD-DWS cases by the average annual  
139 projected population. Serotype-specific circulation variables were created based on the total possible  
140 combinations of each serotype detected per region, or their combination (DENV-1, DENV-2, DENV-  
141 3, DENV-4, DENV-12, DENV-13, DENV-14, DENV-23, DENV-24, DENV-34, DENV-123, DENV-  
142 124, DENV-134, DENV-234, and DENV-1234). Each of these variables were coded as 0, if there was  
143 no presence of circulation, or 1, if there was specific presence of such circulation. Additionally, to assess  
144 which serotype type has the highest risk for elevated cumulative DS-DWS incidence, we created 4  
145 additional variables (circulation of DENV-1 or its combination, circulation of DENV-2 or its  
146 combination, circulation of DENV-3 or its combination, and circulation of DENV-4 or its combination).

147 Additionally, for each region, we adjusted for poverty level and total number of primary care  
148 health facilities per population. The poverty level indicator was based on the INEI categorization of  
149 “poverty with at least one unmet basic need”. A family is “poor” if it has at least 1 of the following  
150 characteristics: 1) home with inadequate construction (exterior walls made of straw mats or “quincha”,  
151 or stone with mud or wood, and dirt floor), 2) overcrowded home (more than 3 to 4 people per room),  
152 3) home without indoor plumbing, 4) home with children who do not attend school, and 5) home with  
153 high economic dependence [19].

154 Regarding number of health facilities, in Peru there are 3 levels of health facilities based on the  
155 complexity of the care and services: 1) primary care facilities, 2) general hospitals or clinics, 3)  
156 specialized hospitals and institutes (e.g., national oncological institute) [20]. We extracted the total  
157 number of primary care facilities per region from the Ministry of Health databases [18]. During  
158 outbreaks, primary care facilities provide care to patients suspected of dengue, provide basic care, and  
159 prevent progression to severe forms of the disease. Finally, per region, the total number of primary  
160 health facilities was divided by the projected population.

161

## 162 **Population and inclusion/exclusion criteria**

163           The study population consisted of Peruvian regions (states) with reports of SD and/or DWS and  
164 dengue serotype identification from 2007 to 2022. Regions without reports of SD-DWS cases and  
165 without identification of circulating serotypes were excluded from the analysis.

166

## 167 **Analytical Approach**

168           For the descriptive analysis, we created summary tables and trend graphs of our variables of  
169 interest. For the main analysis, we explored the association between the cumulative incidence of SD-  
170 DWS per 100,000 inhabitants with each of 16 possible combinations of serotype circulation (see study  
171 variable description above). In a second approach, we explored the association of SD-DWS per  
172 1000,000 inhabitants by the 4 variables that indicated the circulation of each serotype or its combination.  
173 For both analyses, we considered confounding adjustment variables (defined a priori by  
174 epidemiological criteria), such as the poverty level variable (at the region-year level) and the number  
175 of primary health centers per population per region. Given that our outcome variable had  
176 overdispersion, we used mixed negative binomial regression models for repeated measures over time  
177 [21] to estimate crude and adjusted cumulative incidence ratios (IRR) using the “menbreg” command  
178 in Stata (versión 17.0, StataCorp LLC, College Station, TX), for this we also evaluated multicollinearity  
179 among the predictors. The analyses will be performed with a significance level ( $\alpha$ ) of 0.05 and a  
180 confidence level of 95%. The statistical programs used were Stata and R software (version 4.3.2.).

181

182

183

184

185

## 186 Results

187 Overall, 19 regions met our inclusion criteria for the years 2007 to 2022, for a total of 304  
 188 region-years included in our analysis. Five regions (Apurímac, Arequipa, Huancavelica, Moquegua,  
 189 and Tacna) were excluded from the analysis because they either had no reports of SD-DWS cases or no  
 190 serotype information was available.

191

### 192 Dengue cases and cumulative incidence of SD-DWS

193 Five regions account for 65% of reported dengue cases, and almost 80% of both DWS and SD  
 194 in Peru (Table 1). Based on WHO definitions, 87.1%, 12.5%, and only 0.4% were classified as dengue  
 195 without warning signs, DWS, and SD, respectively (Table 1). Some of the regions with highest  
 196 cumulative dengue incidence were different than those with highest absolute numbers, with four having  
 197 greater than 1,334 cases of SD-DWS per 100,000 inhabitants (Table 2 and Fig 1).

198

199 Table 1. Reported dengue cases by WHO classification by region from 2007 to 2022

Regions	Dengue without warning signs	Dengue with warning signs	Dengue severe	Total cases of dengue	Percent by region
Piura	98,293	13,266	330	111,889	24.9%
Loreto	67,712	14,188	517	82,417	18.3%
Ucayali	30,910	7,442	305	38,657	8.6%
Madre de Dios	25,912	5,342	257	31,511	7.0%
San Martín	21,651	4,218	146	26,015	5.8%
Ica	21,167	601	33	21,801	4.9%
Tumbes	20,751	3,015	31	23,797	5.3%
Junín	16,295	2,039	65	18,399	4.1%
La Libertad	15,653	950	36	16,639	3.7%
Cajamarca	13,494	1,870	36	15,400	3.4%
Lambayeque	13,148	231	28	13,407	3.0%
Cusco	10,177	271	22	10,470	2.3%
Amazonas	9,562	509	38	10,109	2.3%
Ayacucho	8,603	270	20	8,893	2.0%
Huánuco	7,087	1,042	33	8,162	1.8%
Ancash	6,069	300	20	6,389	1.4%
Lima	3,544	265	5	3,814	0.9%
Pasco	1,714	205	17	1,936	0.4%
Puno	175	3	0	178	0.04%
Total	391,917	56,027	1,939		
N (%)	(87.1%)	(12.5%)	(0.4%)	449,883	100%

200



201 Table 2. Cumulative incidence of severe dengue and dengue with warning signs (SD-DWS) per  
 202 100,000 inhabitants from 2007 to 2022

Regions	Average population	SD-DWS cases	Cumulative incidence per 100,000 inhabitants
Madre de Dios	145,078	5,599	3,859
Loreto	968,879	14,705	1,518
Ucayali	519,088	7,747	1,492
Tumbes	228,246	3,046	1,335
Piura	188,2302	13,596	722
San Martín	825,404	4,364	529
Junín	130,9566	2,104	161
Huánuco	763,715	1,075	141
Cajamarca	143,2905	1,906	133
Amazonas	413,967	547	132
Pasco	275,340	222	81
Ica	855,401	634	74
La Libertad	1,838,790	986	53
Ayacucho	652,514	290	44
Ancash	1,129,717	320	28
Cusco	1,278,655	293	23
Lambayeque	1,221,466	259	21
Lima	9,603,276	270	3
Puno	1,253,074	3	<1
<b>Total Average</b>	<b>26,597,384</b>	<b>57,966</b>	<b>218</b>

203

204

205


206

207

208

209

210



211

212 **Figure 1.** Cumulative incidence of SD-DWS per 100,000 inhabitants by region from 2007 to  
213 2022

214

## 215 **Serotype circulation**

216 From 2007 to 2022, 58,748 samples were serotyped (14.5% of laboratory-confirmed dengue  
217 cases) and registered in the NETLAB-INS system. During the observation period, DENV-2 serotype  
218 (52.8%) was the most frequently observed, followed by DENV-1 (37.4%), and to a lesser extent DENV-  
219 3 (6.9%) and DENV-4 serotypes (2.9%) (Table 3). In most regions, we observed consistent circulation  
220 of one or more serotypes over time, with one serotype predominating over others; additionally, after

221 novel serotype introductions or reintroductions of a serotype that had not circulated at high rates for a  
 222 few years, we could observe displacement of one serotype by another. For example, in Loreto in 2007,  
 223 DENV-3 was the predominant circulating serotype; it was displaced by DENV-4 in 2008 until 2010,  
 224 and then after a brief period when DENV-1, DENV-2, and DENV-4 were co-circulating at the same  
 225 time, DENV-2 caused a dramatic outbreak and became the predominant serotype in the region for nearly  
 226 a decade (S1 Fig).

227

228 Table 3. Circulating dengue serotypes by region and year registered in the NETLAB-INS system from  
 229 2007 to 2022.

Regions	DENV-1	DENV-2	DENV-3	DENV-4	Total	Percent by region
Loreto	3,127	4,816	112	272	8,327	14.2%
San Martín	1,222	4,004	128	202	5,556	9.5%
Ucayali	881	3,345	128	160	4,514	7.7%
Junín	2,621	2,386	54	109	5,170	8.8%
Madre de Dios	1,787	2,177	271	237	4,472	7.6%
Cajamarca	1,315	1,980	394	54	3,743	6.4%
Lambayeque	206	1,707	719	81	2,713	4.6%
Piura	2,770	1,552	724	291	5,337	9.1%
Cusco	1,296	1,485	22	11	2,814	4.8%
Ayacucho	638	1,223	4	1	1,866	3.2%
Huánuco	869	1,194	31	64	2,158	3.7%
Tumbes	647	1,187	127	55	2,016	3.4%
Lima	1,619	927	418	52	3,016	5.1%
Ancash	1,793	897	17	5	2,712	4.6%
Ica	568	774	2	0	1,344	2.3%
La Libertad	346	738	803	59	1,946	3.3%
Amazonas	137	444	112	32	725	1.2%
Puno	46	141	1	0	188	0.3%
Pasco	64	56	5	6	131	0.2%
Total	21,952	31,033	4,072	1,691	58,748	100%
N (%)	(37.4%)	(52.8%)	(6.9%)	(2.9%)		

230


231 When examining different combinations of serotypes, of the 304 region-years analyzed,  
 232 DENV-12 was the most commonly observed combination of circulating serotypes, which circulated in  
 233 74 region-years (24.3%), followed by DENV-2 (35 region-years), DENV-23 (29 region-years), DENV-  
 234 123 (27 region-years), and DENV-134 (26 region-years), while in 37 region-years (12.2%) no serotype  
 235 circulation was reported (S1 Table).

236

## 237 Serotype circulation attributed to severe dengue

238 Focusing on severe dengue cases alone, the highest frequency of reported SD cases occurred  
239 when there was circulation of DENV-12 (37%), followed by DENV-123 (19.7%) and DENV-23  
240 (12.6%), noting that more SD cases were observed with the involvement of DENV-2 in some  
241 combination or alone (Fig 2).

242



244 **Figure 2.** Frequency of severe dengue cases attributed to specific serotype circulation.

245

## 246 Association between SD-DWS and serotype circulation

247 Table 4 presents results from our mixed negative binomial regression models for the association  
248 between specific serotype circulation and the cumulative incidence of SD-DWS. In the adjusted model,  
249 we observed that there is a higher risk for increased cumulative incidence of SD-DWS in regions where

250 DENV-1, DENV-2, and DENV-3 cocirculated (DENV-123); the average incidence ratio per 100,000  
 251 inhabitants increases by 7.6 times. Note that the circulating types of serotypes DENV-124, DENV-13,  
 252 DENV-24, DENV-4, DENV-3, DENV-34, DENV-234, DENV-14, and DENV-1234, were not included  
 253 in the adjusted model because they circulated infrequently (circulated in less than 6% of the study  
 254 period, S1 Table) and because their inclusion yielded wide confidence intervals. However, in the  
 255 adjusted analysis, when all types of serotype circulation were included, the circulation of serotype 2 or  
 256 its combination showed a high-risk factor for the incidence of SD-DWS (S2 Table). Hence, we  
 257 conducted a separate analysis to evaluate the cumulative incidence risk of SD-DWS due to the  
 258 circulation of DENV-2 alone or in combination with other serotypes and found the average incidence  
 259 ratio per 100,000 inhabitants increases up to 27.7 times (Table 5).

260

261 Table 4. Association between specific serotype circulation and cumulative incidence of severe dengue  
 262 and/or dengue with warning signs.

Variables	Cumulative Incidence of SD-DWS							
	Crude bivariate analysis			Multivariate adjusted analysis				
	IRRc	IC 95%		p	IRRa	IC 95%		p
Circulation of DENV-123								
No	Ref.				Ref.			
Yes	3.17	1.55	- 6.50	0.002	7.57	4.00	- 14.31	<0.001
Circulation of DENV-12								
No	Ref.				Ref.			
Yes	3.27	2.04	- 5.25	<0.001	4.66	2.57	- 8.44	<0.001
Circulation of DENV-23								
No	Ref.				Ref.			
Yes	1.22	0.58	- 2.57	0.599	3.55	1.75	- 7.21	<0.001
Circulation of DENV-2								
No	Ref.				Ref.			
Yes	0.67	0.33	- 1.39	0.288	1.86	0.91	- 3.83	0.091
Circulation of DENV-1								
No	Ref.				Ref.			
Yes	0.07	0.02	- 0.21	<0.001	0.22	0.07	- 0.66	0.007
Circulation of DENV-134								
No	Ref.				Ref.			
Yes	0.01	0.01	- 0.03	<0.001	0.09	0.03	- 0.24	<0.001
Poverty level at the regional level	0.85	0.81	- 0.89	<0.001	0.93	0.89	- 0.97	0.001
Total primary health centers per total population per region	0.97	0.93	- 1.02	0.220	1.00	0.95	- 1.04	0.867

IRRc: Crude cumulative incidence ratios per 100,000 population. IRRa: Adjusted cumulative incidence ratios per 100,000 population. For repeated measures over time, a mixed negative binomial regression model was used.

263

264 Table 5: Association between the circulation of each serotype or its combination with the cumulative  
 265 incidence of severe dengue and/or dengue with warning signs.

Variables	Cumulative Incidence of SD-DWS							
	Crude bivariate analysis				Multivariate adjusted analysis			
	IRRc	IC 95%		p	IRRa	IC 95%		p
Circulation of DENV-1 or its combination								
No	Ref.				Ref.			
Yes	2.19	1.39 - 3.44		3.444	2.34	1.61 - 3.41		<0.001
Circulation of DENV-2 or its combination								
No	Ref.				Ref.			
Yes	51.51	31.35 - 84.62		<0.001	27.70	15.46 - 49.63		<0.001
Circulation of DENV-3 or its combination								
No	Ref.				Ref.			
Yes	0.99	0.59 - 1.66		0.966	1.53	0.98 - 2.38		0.063
Circulation of DENV-4 or its combination								
No	Ref.				Ref.			
Yes	0.22	0.12 - 0.40		<0.001	0.72	0.43 - 1.22		0.225
Poverty level at the regional level	0.85	0.81 - 0.89		<0.001	0.94	0.90 - 0.98		0.002
Total primary health centers per total population per region	0.97	0.93 - 1.02		0.220	0.98	0.93 - 1.03		0.330

IRRc: Crude cumulative incidence ratios per 100,000 population. IRRa: Adjusted cumulative incidence ratios per 100,000 population. A mixed negative binomial regression model was used for repeated measures over time.

266

## 267 Association between SD-DWS and poverty

268 We also observed that as regional poverty increased, the cumulative incidence of SD-DWS  
 269 reduced between 6% (Table 5) and 7% (Table 4). Specifically, in regions with a high level of poverty,  
 270 such as Loreto and Ucayali, there is a trend of lower cumulative incidence of DS-DWS, while in regions  
 271 with a low level of poverty, there is a trend of increasing incidence of DS-DWS (S2 Fig.). To explore  
 272 these results further, we categorized the poverty-level variables into tertiles and re-ran the main model.  
 273 In this new analysis, we found that regions in the highest tertile (wealthier region) had up to 14.2 times  
 274 more DS-DWS incidence than regions in the lowest tertile (Table S3).

275

## 276 Discussion

277 Our results suggest that the population rates of SD-DWS increase when DENV-2 is one of  
278 multiple co-circulating dengue virus serotypes in a region. These findings are consistent with previous  
279 studies in other countries that have evidenced a higher risk of severe dengue related to the circulation  
280 of the DENV-2 serotype [22–24].

281 Although our results indicate a higher risk of disease severity due to the presence of DENV-2,  
282 we could not determine if this was due to the introduction of a novel genotype (Asian/American) and  
283 Cosmopolitan genotypes) because genotyping is limited. Other studies from Peru, however, have  
284 described increased disease severity associated with presentations of the 2010 introduction of  
285 Asian/American DENV-2 to Iquitos [7,25–27]. The 2019 dengue outbreak in Madre de Dios coincided  
286 with the entry of the Cosmopolitan genotype of DENV-2 as well [28]. In 2023, an unprecedented  
287 outbreak in both size and areas affected had a particularly devastating impact on the northern coast of  
288 Peru, with historic highs of reported SD cases and mortality; once again, it was the circulation of the  
289 Cosmopolitan genotype of DENV-2 [2].

290 The lower cumulative incidence of SD-DWS observed in the context of DENV-1 circulation  
291 and the combination of DENV-134 provides additional support for the finding that serotype DENV-2,  
292 or its combination is a major risk factor for severe disease. It is important to note, however, that this  
293 observation is not equivalent to the conclusion that these other serotypes are protective against severe  
294 disease.

295 We showed that when regional poverty increased, the cumulative incidence of SD-DWS  
296 reduced by about 7%. Some studies have found that poor nutritional status can be protective against  
297 severe disease at the individual level [29,30]. Many host and environmental factors associated with  
298 poverty have multiple and complex impacts on dengue virus transmission, requiring detailed and long-  
299 term longitudinal research studies.

300 This study highlights the importance of diagnostic surveillance of circulating DENV serotypes.  
301 As DENV expands to new areas of Peru, as has occurred recently, health personnel with no or limited  
302 experience with dengue must be trained on its management and treatment. Shifts in DENV serotypes

303 or genotypes increase the risk of epidemic transmission because the population likely has lower levels  
304 of immunity toward a serotype that has been absent for multiple years. Additionally, the increased risk  
305 for severe diseases associated with DENV-2 is well established in cohort studies of individuals [22–  
306 24], and our study validates this at the population level.

307         There are various limitations to this study. We used public data aggregated at the population  
308 level and lacked detailed information on the identification of the circulating serotype (or its phenotypic  
309 variants) for each dengue case reported by the epidemiological surveillance system or the identification  
310 of the type of infection (first, second, third, or fourth) of each reported dengue case. The information  
311 obtained about the diagnosed dengue cases comes from the CDC-Peru’s epidemiological surveillance  
312 system; reported by public and private health systems at all levels of care and based on the diagnostic  
313 criteria established by the WHO in 2009 [15]. As a result, variability in the diagnosis/reporting of  
314 dengue cases by health personnel is very likely; however, this would result in a non-differential bias, as  
315 it would affect all dengue diagnostic groups and all study regions similarly [31]. Additionally, the  
316 Peruvian dengue epidemiological surveillance is based on a passive surveillance system: this likely  
317 results in underreporting of dengue cases and identification of the circulating serotype, either because  
318 most dengue cases are asymptomatic (of every 5 people with dengue, only one person is symptomatic  
319 [32]) or due to lack of access to care in the health system (especially in the context of epidemic  
320 outbreaks). Finally, an important limitation is that population-level variables that could influence the  
321 disease severity have not been taken into account in this study, such as the population at risk of second  
322 infections (risk factor for severe dengue at the individual level) or vector control actions carried out  
323 regionally (street and home fumigation, water treatment, and breeding site collection campaigns), which  
324 are known to help reduce transmission intensity during an epidemic outbreak.

325

326

327



## 328 **Acknowledgments**

329 We thank the National Institute of Health of the Peruvian Ministry of Health and the CDC-  
330 Peru for sharing data from their epidemiological surveillance system for dengue.

331

332

## 333 **Funding**

334 This study is part of Jorge L. Cañari-Casaño PhD thesis in Epidemiological Research

335 Doctorate at Universidad Peruana Cayetano Heredia under FONDECYT/CIENCIACTIVA

336 scholarship EF033-235-2015 and supported by training grant D43 TW007393 awarded by the Fogarty

337 International Center of the US National Institutes of Health.

338

## 339 **Data Availability**

340 The final dataset used is available on <https://doi.org/10.6084/m9.figshare.25336015.v4>

341

342

343

344

345

346

347

348

349

350

## 351 References

- 352 1. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B, Ham Tu B, Chi Minh City H.  
353 Dengue. *New England Journal of Medicine* [Internet]. 2012 Apr 12 [cited 2024 Apr  
354 25];366(15):1423–32. Available from:  
355 <https://www.nejm.org/doi/full/10.1056/NEJMra1110265>
- 356 2. Cabezas Sánchez C, Cabezas Sánchez C. Dengue en el Perú: crónica de epidemias  
357 recurrentes (1990 -2023), el virus, el *Aedes aegypti* y sus determinantes, ¿a dónde  
358 vamos? *Anales de la Facultad de Medicina* [Internet]. 2023 Jul 1 [cited 2023 Nov  
359 6];84(2):145–8. Available from:  
360 [http://www.scielo.org.pe/scielo.php?script=sci\\_arttext&pid=S1025-](http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1025-55832023000200145&lng=es&nrm=iso&tlng=es)  
361 [55832023000200145&lng=es&nrm=iso&tlng=es](http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1025-55832023000200145&lng=es&nrm=iso&tlng=es)
- 362 3. César C, Fiestas V, García-Mendoza M, Palomino M, Mamani E, Donaires F. Dengue  
363 in peru: a quarter century after its reemergence. *Rev Peru Med Exp Salud Publica*  
364 [Internet]. 2015 Apr 2 [cited 2023 Aug 8];32(1):146–56. Available from:  
365 <https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/1587/1857>
- 366 4. Vazquez-Prokopec GM, Morrison AC, Paz-Soldan V, Stoddard ST, Koval W, Waller  
367 LA, et al. Inapparent infections shape the transmission heterogeneity of dengue.  
368 *PNAS Nexus* [Internet]. 2023 Mar 1 [cited 2024 Apr 25];2(3). Available from:  
369 </pmc/articles/PMC10003742/>
- 370 5. Liebman KA, Stoddard ST, Morrison AC, Rocha C, Minnick S, Sihuincha M, et al.  
371 Spatial dimensions of dengue virus transmission across interepidemic and epidemic  
372 periods in iquitos, peru (1999-2003). *PLoS Negl Trop Dis*. 2012 Feb;6(2).
- 373 6. Morrison AC, Minnick SL, Rocha C, Forshey BM, Stoddard ST, Getis A, et al.  
374 Epidemiology of Dengue Virus in Iquitos, Peru 1999 to 2005: Interepidemic and  
375 Epidemic Patterns of Transmission. *PLoS Negl Trop Dis* [Internet]. 2010 May [cited  
376 2021 Jul 26];4(5). Available from: </pmc/articles/PMC2864256/>
- 377 7. Velazco SD, Solórzano VF, Maldonado MS, Lencinas CC, Vela VV, Flores CT, et al.  
378 Impacto de la epidemia de dengue con un nuevo linaje del DENV-2 genotipo  
379 Americano / Asiático en la demanda de servicios del Hospital de Apoyo de Iquitos  
380 “César Garayar García.” *Rev Peru Med Exp Salud Publica* [Internet]. 2011 Mar 31  
381 [cited 2021 Jul 26];28(1):156–66. Available from:  
382 <https://rpmesp.ins.gob.pe/rpmesp/article/view/474>
- 383 8. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V,  
384 et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in  
385 Rayong, Thailand. The 1980 outbreak. *Am J Epidemiol* [Internet]. 1984 Nov 1 [cited  
386 2021 Jul 25];120(5):653–69. Available from:  
387 <https://academic.oup.com/aje/article/120/5/653/90744>
- 388 9. Guzmán M, Kourí G, Valdés L, Bravo J, Vázquez S, Halstead S. Enhanced severity of  
389 secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. *Rev*  
390 *Panam Salud Publica* [Internet]. 2002 [cited 2021 Jul 25];11(4):223–7. Available from:  
391 <https://pubmed.ncbi.nlm.nih.gov/12049030/>
- 392 10. Soo KM, Khalid B, Ching SM, Chee HY. Meta-Analysis of Dengue Severity during  
393 Infection by Different Dengue Virus Serotypes in Primary and Secondary Infections.  
394 *PLoS One*. 2016 May 1;11(5):e0154760.
- 395 11. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue  
396 hemorrhagic fever/dengue shock syndrome: an historical perspective and role of

- 397 antibody-dependent enhancement of infection. *Archives of Virology* 2013 158:7  
398 [Internet]. 2013 Mar 8 [cited 2023 Aug 8];158(7):1445–59. Available from:  
399 <https://link.springer.com/article/10.1007/s00705-013-1645-3>
- 400 12. Tsheten T, Clements A, Gray D, Adhikary R, Furuya-Kanamori L, Wangdi K. Clinical  
401 predictors of severe dengue: a systematic review and meta-analysis. *Infect Dis*  
402 *Poverty* [Internet]. 2021 Dec 1 [cited 2021 Oct 31];10(1). Available from:  
403 <https://pubmed.ncbi.nlm.nih.gov/34627388/>
- 404 13. Kanakarathne N, Wahala WMPB, Messer WB, Tissera HA, Shahani A, Abeysinghe N,  
405 et al. Severe Dengue Epidemics in Sri Lanka, 2003–2006 - Volume 15, Number 2—  
406 February 2009 - *Emerging Infectious Diseases journal - CDC*. *Emerg Infect Dis*  
407 [Internet]. 2009 Feb [cited 2023 Aug 8];15(2):192–9. Available from:  
408 [https://wwwnc.cdc.gov/eid/article/15/2/08-0926\\_article](https://wwwnc.cdc.gov/eid/article/15/2/08-0926_article)
- 409 14. Ministerio de Salud del Perú. Norma técnica de salud para la vigilancia  
410 epidemiológica Y diagnóstico de laboratorio de dengue, chikungunya, zika y otras  
411 arbovirosis en el Perú [Internet]. 2017 [cited 2024 Mar 17]. Available from:  
412 <https://www.dge.gob.pe/portal/docs/tools/arbovirosis18.pdf>
- 413 15. World Health Organization (WHO). Dengue guidelines for diagnosis, treatment,  
414 prevention and control [Internet]. Geneva; 2009 p. 1–147. Available from:  
415 [www.who.int/tdr](http://www.who.int/tdr)
- 416 16. Mamani E, Figueroa D, García MP, Garaycochea M del C, Pozo EJ. Infecciones  
417 concurrentes por dos serotipos del virus dengue durante un brote en el noroeste de  
418 Perú, 2008. *Rev Peru Med Exp Salud Publica* [Internet]. 2010 [cited 2024 Mar  
419 17];27(1):16–21. Available from:  
420 [http://www.scielo.org.pe/scielo.php?script=sci\\_arttext&pid=S1726-](http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342010000100004&lng=es&nrm=iso&tlng=es)  
421 [46342010000100004&lng=es&nrm=iso&tlng=es](http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342010000100004&lng=es&nrm=iso&tlng=es)
- 422 17. Vargas-Herrera J, Segovia-Juarez J, Garro Nuñez GM. Sistema de información de la  
423 red nacional de laboratorios de salud pública en el Perú (NETLAB). *Rev Peru Med*  
424 *Exp Salud Publica* [Internet]. 2015 Jun 19 [cited 2024 Feb 23];32(2):378–84. Available  
425 from: <https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/1636/1817>
- 426 18. Ministerio de Salud del Perú. Portal del Estado Peruano - Portal de Transparencia del  
427 Ministerio de Salud [Internet]. 2023 [cited 2024 Mar 17]. Available from:  
428 [https://transparencia.gob.pe/reportes\\_directos/pep\\_transparencia\\_acceso\\_informacio](https://transparencia.gob.pe/reportes_directos/pep_transparencia_acceso_informacion.aspx?id_entidad=143&id_tema=49&cod_rueep=0&ver=)  
429 [n.aspx?id\\_entidad=143&id\\_tema=49&cod\\_rueep=0&ver=](https://transparencia.gob.pe/reportes_directos/pep_transparencia_acceso_informacion.aspx?id_entidad=143&id_tema=49&cod_rueep=0&ver=)
- 430 19. Instituto Nacional de Estadística e Informática - INEI Perú. Multidimensionalidad de la  
431 Pobreza [Internet]. 2014 [cited 2024 Mar 17]. p. 83–96. Available from:  
432 [https://www.inei.gob.pe/media/MenuRecursivo/publicaciones\\_digitales/Est/Lib1306/ca](https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/Lib1306/ca)  
433 [p04.pdf](https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/Lib1306/ca)
- 434 20. Ministerio de Salud del Perú. Norma Técnica: Categorías de establecimientos del  
435 sector salud (NT N° 021-MINSA/DGSP V.01) [Internet]. 2005 [cited 2024 Mar 17].  
436 Available from: [https://www.gob.pe/institucion/minsa/informes-publicaciones/352897-](https://www.gob.pe/institucion/minsa/informes-publicaciones/352897-categorias-de-establecimientos-del-sector-salud-nt-n-021-minsa-dgsp-v-01)  
437 [categorias-de-establecimientos-del-sector-salud-nt-n-021-minsa-dgsp-v-01](https://www.gob.pe/institucion/minsa/informes-publicaciones/352897-categorias-de-establecimientos-del-sector-salud-nt-n-021-minsa-dgsp-v-01)
- 438 21. Salinas Ruíz J, Montesinos López OA, Hernández Ramírez G, Crossa Hiriart J.  
439 Generalized Linear Mixed Models for Repeated Measurements. *Generalized Linear*  
440 *Mixed Models with Applications in Agriculture and Biology* [Internet]. 2023 [cited 2024  
441 Feb 23];377–423. Available from: [https://link.springer.com/chapter/10.1007/978-3-](https://link.springer.com/chapter/10.1007/978-3-031-32800-8_9)  
442 [031-32800-8\\_9](https://link.springer.com/chapter/10.1007/978-3-031-32800-8_9)
- 443 22. Balmaseda A, Hammond SN, Pérez L, Tellez Y, Saborío SI, Mercado JC, et al.  
444 Serotype-specific differences in clinical manifestations of dengue. *Am J Trop Med Hyg*

- 445 [Internet]. 2006 Mar 1 [cited 2023 Aug 8];74(3):449–56. Available from:  
446 <https://www.ajtmh.org/view/journals/tpmd/74/3/article-p449.xml>
- 447 23. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisyakorn U, Scott RM, et al.  
448 Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand  
449 from 1973 to 1999. *Am J Trop Med Hyg* [Internet]. 2003 Feb 1 [cited 2023 Aug  
450 8];68(2):191–202. Available from:  
451 <https://www.ajtmh.org/view/journals/tpmd/68/2/article-p191.xml>
- 452 24. Vicente CR, Herlinger KH, Fröschl G, Romano CM, Cabidelle A de SA, Junior CC.  
453 Serotype influences on dengue severity: A cross-sectional study on 485 confirmed  
454 dengue cases in Vitória, Brazil. *BMC Infect Dis* [Internet]. 2016 Jul 8 [cited 2023 Nov  
455 6];16(1):1–7. Available from:  
456 <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1668-y>
- 457 25. Mamani E, Álvarez C, García M. M, Figueroa D, Gatti M, Guio H, et al. Circulación de  
458 un linaje diferente del virus dengue 2 genotipo América / Asia en la región amazónica  
459 de Perú, 2010. *Rev Peru Med Exp Salud Publica* [Internet]. 2011 [cited 2023 Aug  
460 8];28(1):72–7. Available from:  
461 [http://www.scielo.org.pe/scielo.php?script=sci\\_arttext&pid=S1726-  
462 46342011000100011&lng=es&nrm=iso&tlng=es](http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342011000100011&lng=es&nrm=iso&tlng=es)
- 463 26. Williams M, Mayer S V., Johnson WL, Chen R, Volkova E, Vilcarromero S, et al.  
464 Lineage II of Southeast Asian/American DENV-2 is Associated with a Severe Dengue  
465 Outbreak in the Peruvian Amazon. *Am J Trop Med Hyg* [Internet]. 2014 Sep 3 [cited  
466 2024 Apr 30];91(3):611–20. Available from:  
467 <https://www.ajtmh.org/view/journals/tpmd/91/3/article-p611.xml>
- 468 27. Solórzano VF, Maldonado MS, Toscano FD, Velazco SD, María García M, Mamani E,  
469 et al. [Clinical characteristics of patients admitted to hospital “Cesar Garayar García”,  
470 Iquitos during the dengue epidemic, January-February 2011]. *Rev Peru Med Exp  
471 Salud Publica* [Internet]. 2011 [cited 2024 Apr 30];28(1):78–82. Available from:  
472 <https://pubmed.ncbi.nlm.nih.gov/21537773/>
- 473 28. Paquita García M, Padilla C, Figueroa D, Manrique C, Cabezas C. Emergencia del  
474 genotipo Cosmopolitano del virus dengue serotipo 2 (DENV2) en Madre de Dios, Perú,  
475 2019. *Rev Peru Med Exp Salud Publica* [Internet]. 2022 Mar 17 [cited 2023 Aug  
476 8];39(1):126–8. Available from:  
477 <https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/10861/4917>
- 478 29. Chiu YY, Lin CY, Yu LS, Wang WH, Huang CH, Chen YH. The association of obesity  
479 and dengue severity in hospitalized adult patients. *Journal of Microbiology,  
480 Immunology and Infection*. 2023 Apr 1;56(2):267–73.
- 481 30. Chen CY, Chiu YY, Chen YC, Huang CH, Wang WH, Chen YH, et al. Obesity as a  
482 clinical predictor for severe manifestation of dengue: a systematic review and meta-  
483 analysis. *BMC Infect Dis* [Internet]. 2023 Dec 1 [cited 2023 Nov 24];23(1). Available  
484 from: <https://pubmed.ncbi.nlm.nih.gov/37525106/>
- 485 31. Hernández-Avila M, Garrido F, Salazar-Martínez E. Sesgos en estudios  
486 epidemiológicos. *Salud Publica Mex*. 2000 Jan;42(1):438–46.
- 487 32. Stoddard ST, Forshey BM, Morrison AC, Paz-Soldan VA, Vazquez-Prokopec GM,  
488 Astete H, et al. House-to-house human movement drives dengue virus transmission.  
489 *Proc Natl Acad Sci U S A* [Internet]. 2013 Jan 15 [cited 2023 Aug 8];110(3):994–9.  
490 Available from: <https://www.pnas.org/doi/abs/10.1073/pnas.1213349110>  
491

## 492 **Supporting information**

493 **S1 Fig.** Circulation proportion of dengue serotypes in Peru from 2007 to 2022.

494 **S2 Fig.** Trends and correlations between the cumulative incidence of SD-DWS per 100,000 inhabitants  
495 and poverty at the regional level from 2007 to 2022.


496 **S1 Table.** Serotype-specific circulation and severe dengue cases.

497 **S2 Table.** Association between all serotype-specific circulation types and cumulative incidence of SD-  
498 DWS


499 **S3 Table.** Association between serotype-specific circulation types and cumulative incidence of SD-  
500 DWS considering the poverty level variables as a categorical variable of poverty tertiles.

501

S1 Fig. Circulation proportion of dengue serotypes in Peru from 2007 to 2022.



S2 Fig: Trends and correlations between the cumulative incidence of DS-DWS per 100,000 inhabitants and poverty at the regional level from 2007 to 2022.



S1 Table: Serotype-specific circulation and severe dengue cases.

Serotype-specific circulation	Years-region-specific circulation of serotypes		Cases of severe dengue		
	n	Frequency	n	Frequency	
1 serotype	DENV-1	19	6.3%	5	0.3%
	DENV-2	35	11.5%	91	4.7%
	DENV-3	4	1.3%	1	0.1%
	DENV-4	3	1.0%	0	0.0%
2 serotypes	DENV-12	74	24.3%	717	37.0%
	DENV-13	6	2.0%	6	0.3%
	DENV-14	11	3.6%	29	1.5%
	DENV-23	29	9.5%	244	12.6%
	DENV-24	5	1.6%	163	8.4%
	DENV-34	2	0.7%	0	0.0%
3 serotypes	DENV-123	27	8.9%	382	19.7%
	DENV-124	9	3.0%	36	1.9%
	DENV-134	26	8.6%	65	3.4%
	DENV-234	1	0.3%	0	0.0%
4 serotypes	DENV-1234	16	5.3%	196	10.1%
No circulation of serotypes		37	12.2%	4	0.2%
Total		304	100.0%	1939	100.0%



S2 Table: Association between all serotype-specific circulation types and cumulative incidence of SD-

DWS

Variables	Cumulative Incidence of SD-DWS				
	Multivariate adjusted analysis				
	IRRa	IC 95%		p	
Circulation of DENV-123	243.67	53.12	-	1117.71	<0.001
Circulation of DENV-24	142.59	21.67	-	938.21	<0.001
Circulation of DENV-12	128.99	29.07	-	572.31	<0.001
Circulation of DENV-23	91.51	19.87	-	421.49	<0.001
Circulation of DENV-124	57.64	10.43	-	318.60	<0.001
Circulation of DENV-2	43.42	9.52	-	197.97	<0.001
Circulation of DENV-1	7.59	1.41	-	40.76	0.018
Circulation of DENV-14	6.80	1.15	-	40.37	0.035
Circulation of DENV-134	2.97	0.56	-	15.79	0.201
Circulation of DENV-13	5.84	0.57	-	59.40	0.136
Circulation of DENV-4	0.00	0.00	-	0.00	1.000
Circulation of DENV-3	0.58	0.00	-	198.34	0.854
Circulation of DENV-34	1.49	0.01	-	154.60	0.867
Circulation of DENV-234	0.00	0.00	-	0.00	0.999
Circulation of DENV-1234	114.16	22.90	-	568.99	<0.001
Poverty rate at the regional level	0.95	0.91	-	0.99	0.013
Total primary health centers over the total population at the regional level	0.99	0.96	-	1.03	0.797

IRRa: Adjusted cumulative incidence ratios per 100,000 population. A mixed negative binomial regression model was used for repeated measures over time.

**S3 Table.** Association between serotype-specific circulation types and cumulative incidence of DS-DWS considering the poverty level variables as a categorical variable of poverty tertiles.

Variables	Multivariate adjusted analysis		
	IRRa	IC 95%	p
Circulation of DENV-123			
No	Ref.		
Yes	9.38	5.13 - 17.14	<0.001
Circulation of DENV-12			
No	Ref.		
Yes	5.90	3.53 - 9.86	<0.001
Circulation of DENV-23			
No	Ref.		
Yes	4.36	2.28 - 8.35	<0.001
Circulation of DENV-2			
No	Ref.		
Yes	1.94	1.01 - 3.73	0.047
Circulation of DENV-1			
No	Ref.		
Yes	0.27	0.10 - 0.76	0.013
Circulation of DENV-134			
No	Ref.		
Yes	0.11	0.04 - 0.28	<0.001
Poverty tercile at regional level			
1 (wealthier)	14.18	4.56 - 44.11	<0.001
2	8.97	4.09 - 19.66	<0.001
3 (poorer)	Ref.		
Total primary health centers over the total population at the regional level	1.00	0.95 - 1.04	0.867

IRRa: Adjusted cumulative incidence ratios per 100,000 population. A mixed negative binomial regression model was used for repeated measures over time.